SLC5A2 and diabetes mellitus: In experimental models of diabetes, SGLT2 inhibitors have been shown to reduce albuminuria, mesangial dilation, and matrix accumulation [11], which could not be readily explained by the action of SGLT2 inhibitor on the proximal tubules, but by the effects on glomerular hemodynamics, probably coupled with the inhibition of renal inflammation and oxidative stress [12].